MCAS Article 2: Antihistamines for ME/CFS and MCAS: H1 vs H2, and Why Your Doctor Raises the Dose
If you have ME/CFS and MCAS — or even just some of the allergic-style symptoms — the first thing you’re likely to be handed is an antihistamine. And the prescription, or the advice, will probably come with the confusing phrase “H1 and H2.”
This article explains the medications themselves: what histamine is and where its two relevant receiver points live, the H1 and H2 antihistamines, and the mast-cell stabilisers that work one step earlier. It also answers the question people ask most: why does my doctor want to raise the dose above what the box says?
For the conceptual background — what MCAS is, why it appears after ME/CFS, and the difference between MCAS-alone and ME/CFS-with-MCAS — see the companion overview article. And for the honest “what if it doesn’t work” discussion, see the companion article on treatment failure.
1 First, a plain warning
Everything below is a medicine you will likely be offered, not self-medication advice. Histamine is not the only chemical involved here, antihistamines are not harmless water, and I am not a doctor. Talk to a prescriber before starting, stopping, or changing any of these drugs. If your symptoms feel sudden, severe, or life-threatening — especially any breathing difficulty or swelling in the throat — that is an emergency. Go to a hospital. This article is an explanation, not a prescription. And in ME/CFS, the wrong diagnosis or the wrong drug can set you back, so work with someone who takes the condition seriously.
2 What is histamine, and where does it live?
Histamine is a small chemical messenger. It is made by mast cells, but it is also made by certain white blood cells (basophils) and stored across the body. Its job in health is normal and useful: it helps widen tiny blood vessels, helps stomach acid secretion, and acts as a nervous-system signal.
Histamine does its work by docking onto receptors — receiver ports on the outside of cells. There are four known kinds, H1 through H4. For your purposes, only two matter:
Where histamine and its receptors do their work:
- H1 receptors live on the smooth muscle of your airways, your skin blood vessels, your nose, and your eyes. When histamine lands on H1, you get itching, flushing, hives, a runny nose, sneezing, and airway tightening. H1 blockers treat these allergy symptoms (Molderings et al. 2016).
- H2 receptors live mainly in your stomach lining (governing acid secretion) and on immune cells. When histamine lands on H2, it pushes stomach acid up and talks to immune cells. H2 blockers are the drugs you might know as heartburn pills. In mast-cell treatment, they are used alongside H1 blockers because mast cells fire histamine at both sites (Simons and Simons 2019).
Why people say “H1 and H2 together”: a mast cell dumps histamine everywhere at once. Blocking only the H1 site leaves the H2 sites in the stomach and on immune cells still being hit. For this reason, mast-cell care commonly (not always) pairs an H1 antihistamine with an H2 antihistamine (Molderings et al. 2016). Be clear about what that’s based on: the H1+H2 combination is common clinical practice, but as the limitations below note, the added benefit of the H2 part specifically is not backed by high-grade evidence — it’s a reasonable practice, not a proven necessity.
3 The H1 antihistamines
What they are. These are the “allergy pills.” Cetirizine, loratadine, fexofenadine, bilastine, levocetirizine, desloratadine. The second-generation ones are the ones usually used long-term because they are designed not to cross into the brain much, so they cause less drowsiness (Podder, Dhabal, and Chakraborty 2023).
What they’re for. Flushing, itching, hives, runny nose, sneezing, throat tightness — the classic histamine-dumped-on-H1 symptoms.
How they work. They do not stop histamine being released. They do not stop mast cells firing. They sit on the H1 receptor and block histamine from docking there. The histamine is still in your blood; it just can’t reach one of its targets (Molderings et al. 2016).
A key trick doctors know — and why high doses are necessary. In chronic urticaria (hives with no obvious cause), standard doses often fail, and the international guidelines recommend raising the dose to two, three, or even four times the normal amount (Zuberbier et al. 2022). The up-dosing has real evidence: a systematic review found grade-A support for cetirizine, fexofenadine, and bilastine at higher doses, with fexofenadine reaching an 83% responder rate (Podder, Dhabal, and Chakraborty 2023).
Why does more help? A useful, simplified picture: think of the H1 receptor as a lock and histamine as a key. An antihistamine is a blocking key that fits the same lock, sits there, and stops real keys getting in. When mast cells fire hugely there is much more histamine than usual, so more blocker is needed to keep most locks filled. (Strictly, second-generation H1 antihistamines are high-affinity inverse agonists and the real pharmacology is subtler than a simple plug-and-key — this analogy is for intuition, not mechanism.) Whatever the precise chemistry, the practical, well-evidenced point stands: in chronic urticaria a standard dose is often outnumbered and raising the dose recovers control — which is why the guidelines and MCAS clinicians escalate.
This is why up-dosing works in chronic urticaria and why MCAS clinicians use the same idea — though it must be done under supervision, and the specific evidence base in MCAS itself is much thinner than in urticaria (Nurmatov et al. 2015). The 83% figure is from urticaria trials, where those patients were already unresponsive at standard dose; that context, not an absolute promise, is what the number means. An important safety note: at standard dose second-generation H1s rarely sedate, but at severalfold doses sleepiness and other side effects rise — and sedation is a heavy cost in ME/CFS. The safety data for up to fourfold dosing is reassuring (in one series, only 10% reported any side effect, mostly drowsiness, with no serious events), but it is not risk-free — and those figures come from urticaria populations, not the drug-sensitive ME/CFS population, so treat them as indicative rather than binding [Elzen et al. (2017)](Podder, Dhabal, and Chakraborty 2023). Up-dosing is not for everyone: people with kidney impairment (cetirizine and levocetirizine build up), the elderly (sedation, falls, urinary retention), and anyone pregnant or breastfeeding need a prescriber’s explicit review before a raised dose — and nobody should adjust their own dose upward without that review. A structured trial goes up slowly (generally one step at a time, assessed over a week or two each) and stops if sedation outweighs benefit. Practically, this also means no driving or operating machinery until you know how the raised dose affects you, as sedation at severalfold doses is common and unpredictable.
The honest limitation. A systematic review found only five small trials of H1 antihistamines specifically in mast-cell activation syndromes — so while these drugs are widely used and clearly stop the “histamine on the skin/nose” symptoms, the high-quality evidence specifically for MCAS is weak (Nurmatov et al. 2015).
4 The H2 antihistamines
What they are. Famotidine and cimetidine. You recognise them as heartburn medicines. (Ranitidine, a once-common H2 blocker, was withdrawn worldwide in 2019–2020 over a cancer-risk contamination; any pill in an old drawer labelled ‘ranitidine’ should not be taken.) In mast-cell treatment they play a second role.
What they’re for. Together with an H1 blocker, they reduce stomach symptoms (heartburn, reflux, bloating) and calm the immune-cell side of histamine signalling (Simons and Simons 2019).
How they work. They sit on the H2 receptor in the stomach and on immune cells, blocking histamine there. Their immune effects are real but complex: blocking H2 changes how some T and B immune cells behave (Pol et al. 2021).
The honest limitation. Famotidine and its relatives are very safe and well studied as ulcer/heartburn drugs. Whether added H2 blockade meaningfully improves mast-cell symptoms on top of an H1 blocker is less rigorously proven — it’s good clinical practice, but not high-grade evidence (Simons and Simons 2019).
A distinct idea: the H2-responder subgroup. Because H2 receptors also sit on immune cells, a small body of clinical thinking proposes that some ME/CFS patients — characteristically those with post-infectious onset (after EBV or other herpesviruses), pronounced POTS, and histamine issues — may be unusually helped by the specific H2 blocker cimetidine. The suggested mechanism is twofold: blocking H2 on certain immune cells may boost a flagging cellular immune response to a chronically reactivating virus, while the mast-cell/histamine pathway addresses the metabolic side [Goldstein (1986)](Simons and Simons 2019). Be sceptical here: this phenotype rests on a 1986 claim plus mechanism, and roughly four decades later no controlled trial has confirmed it. Note the honest reading of that silence: it could mean the effect is rare or weak — but a cheap generic has little commercial incentive to be tested, so it could equally mean no adequate trial was ever run. Either way, it is a hypothesis from case reports, not a rule, and it is a poor reason to choose cimetidine over a safer H2. And cimetidine has a hard safety limit: unlike famotidine, it is a potent inhibitor of several liver enzymes (CYP1A2, 2C9, 2D6, 3A4), so it raises blood levels of warfarin, theophylline, many antidepressants, beta-blockers and antiarrhythmics, and others, and with long-term use it can have anti-androgen effects. In an ME/CFS/POTS patient who is often already on several of these, the prescriber must review the full medication list before any cimetidine is used; famotidine is the safer default for this reason. (Loth 2026)
5 The mast-cell stabilisers
Antihistamines block the chemicals after they’re released. A different family of drugs tries to stop the burst itself.
- Cromolyn (cromoglycate) — a mast-cell stabiliser, often taken orally for gut symptoms or inhaled/nebulised for lung ones. It tries to stop mast cells degranulating (Molderings et al. 2016).
- Ketotifen — an H1 antihistamine plus a mast-cell stabiliser. It is frequently used in mast-cell / POTS care (Weinstock et al. 2024). Sedation is a real issue: ketotifen is strongly sedating for many people, so it is usually started at night at a low dose and raised slowly. For an ME/CFS patient, that daytime sedation can be more costly than the benefit, so it needs careful trialling with your clinician.
- Rupatadine — an H1 antihistamine that also blocks a second mediator (PAF). Higher-dose benefit has been studied mainly in mastocytosis (a more severe, clonal disease), which is a reasonable but not identical basis for its MCAS use (Izquierdo et al. 2024).
- Montelukast — blocks leukotrienes, another mast-product family; sometimes added when histamine blockers are insufficient (drawn from case-series practice, not MCAS-specific trials) (Afrin 2013). It carries a US boxed warning for serious mood and behaviour changes (agitation, depression, in rare cases suicidal thoughts); anyone on it should stop and report immediately if mood or behaviour changes.
The honest limitation — and it’s an important one. In severe or resistant cases, stronger drugs (omalizumab, an antibody that targets the allergy pathway) show response in case series (Matheny, Craig, and Al-Shaikhly 2025). But the highest-level trials of mast-cell stabilisers in overlapping conditions have been disappointing: a randomized trial of ketotifen in fibromyalgia found no overall benefit beyond placebo (Moldofsky et al. 2015). That is a sobering, honest data point, and we’ll come back to what it means in the companion article on treatment failure.
6 The symptoms that antihistamines might touch, and the ones they won’t
What they might help (if your symptoms are mast-cell driven): flushing, itching, hives, a stuffy or running nose, some headaches, gut cramping and reflux, and possibly some orthostatic symptoms, because histamine and prostaglandin D₂ work to dilate vessels and drop blood pressure (Kohno et al. 2021). In one long-COVID/MCAS cohort treated with fexofenadine plus famotidine, subsets of patients reported resolution of fatigue, brain fog, and tachycardia — though the study had no control group, so it can’t prove cause and effect (Salvucci et al. 2023).
Set expectations honestly, because the hostile evidence exists. The only randomized trial of an H1 antihistamine specifically in chronic fatigue syndrome — a 1996 double-blind study — found no benefit at all, and it has never been overturned by a positive MCAS-specific RCT (Steinberg et al. 1996). The long-COVID improvements above are uncontrolled, and the positive up-dosing data come from chronic urticaria, not ME/CFS. What this means: “worth trying for the allergic-profile subgroup” is a reasonable hope, but the honest prior is modest and not guaranteed — which is exactly why a structured trial with a stop-rule (below) matters, and why a failed trial is an ordinary outcome, not a personal failure.
What they usually will NOT fix single-handedly: the core energy production problem in ME/CFS, whatever its precise mechanism. Even where histamine blockade helps symptoms, it does not directly address the cellular energy and immune dysfunctions that are widely proposed to sit at the centre of the illness (Loth 2026). No mast-cell drug is sold as a cure for ME/CFS, and the careful perspective is that this is part of the picture for some people — not the whole disease (Castells et al. 2024).
7 Expected results
Be realistic, and be patient. Mast-cell care in ME/CFS is usually described as a trial, not a guaranteed treatment. What that looks like in practice:
- A trial is given time. Response is typically assessed over weeks to months, not days. A single afternoon of “it did nothing” tells you little.
- It may be a partial effect. You might get the flushing and the headaches down, still have the fatigue, and count that as a win.
- Higher doses are sometimes needed for the H1 blockers, under supervision, and they must be escalated with care because they can cause sedation — and sedation is the last thing an ME/CFS patient needs (Zuberbier et al. 2022).
- Combining H1 + H2 (and sometimes a stabiliser) is common but not firmly evidence-backed — the H2 part especially rests on practice, not strong trials (Molderings et al. 2016).
- Expectation matters. The clinical expectation — not yet proven by a prospective trial — is that mast-cell treatment is most likely to help people who also have clear episodic allergic-type symptoms (flushing, hives, histamine-style reactions) [Rohrhofer et al. (2025)](Weinstock, Nelson, and Blitshteyn 2023). Whether that “allergic profile” genuinely predicts response has not been tested in a controlled study, so treat it as a reasonable prior, not a guarantee. If you have none of those symptoms, that makes a dramatic response less likely on those grounds — but it is not an override of the evidence uncertainty above.
8 An example “structured trial” — and rule-things-out-first
This is an example to give your clinician something to work from — not a self-prescription. The prescriber chooses the drug, dose, and duration.
A practical frame a doctor can write: pick one target symptom (e.g., flushing, hives, or gut cramping). Start a single second-generation H1 (for example fexofenadine 180 mg daily, or the prescriber’s preferred choice). Reassess the single target symptom at 4–6 weeks. Only after titration to the maximally tolerated dose (which for these drugs may be up to fourfold the starting dose, per the up-dosing section above — the starting dose is not the target dose) is the drug judged. If there is no improvement at that tolerated higher dose, the stop-rule fires: stop that agent (or try a different second-generation H1 — failure of one molecule is not failure of the class), rather than adding another drug, which is a cleaner answer. If the drug helps at standard dose, there is no reason to raise it. Only once an adequately-dosed H1 is genuinely not helping does the conversation move to adding an H2 or a stabiliser. All higher dosing happens with the prescriber, never by self-escalation.
Things to rule out first / know before up-dosing: certain diseases produce the same flushing-and-episodic-symptoms picture and must not be treated as “just MCAS” — notably systemic mastocytosis (a baseline tryptase blood test is widely available and is the first screen), true IgE food allergy, thyroid disease, and, rarely, hormone-secreting tumours (carcinoid, phaeochromocytoma). A prescriber should rule these out or exclude them before committing to chronic antihistamine treatment.
When to refer onward: recurrent severe reactions, an elevated baseline tryptase, fainting/syncope with reactions, or failure of well-conducted first- and second-line agents all warrant referral to an allergist-immunologist with MCAS experience, rather than continued empirical dosing in primary care.
If you’re also on POTS medication (fludrocortisone, midodrine, beta-blockers), the blood-pressure and sedation effects of an up-dosed antihistamine and any cimetidine interaction need to be assessed together — this is a case for one clinician holding the full medication list, not a self-directed supplement stack.
9 The bottom line
Antihistamines — the H1s and the H2s — are real drugs that block histamine at two different receiver sites. They calm the allergic-style symptoms, not the energy crisis (Molderings et al. 2016). Higher doses are sometimes genuinely necessary because a mast-cell storm simply outnumbers a standard dose, but that up-dosing must be done under supervision and carries a sedation cost. And the honest truth is that the specific evidence for these drugs in MCAS-on-top-of-ME/CFS is thinner than the urticaria evidence that many dosing rules are borrowed from (Nurmatov et al. 2015).
They are worth taking seriously as part of the picture for people who have the episodic allergic profile. But they are not a cure, and a failed trial tells you more than “the drugs don’t work” — it points you toward the more nuanced questions covered in the companion article on what it means when they don’t help.
For the comprehensive, fully-cited picture of how mast cells are weighed among the many candidate mechanisms in ME/CFS, see (Loth 2026).